May 8, 2017 / 12:22 PM / 3 months ago

BRIEF-Ocular Therapeutix presents additional phase 3 data results for Dextenza

May 8 (Reuters) - Ocular Therapeutix Inc

* Ocular Therapeutix presents additional phase 3 data and patient reported outcomes results for Dextenza at the American Society of Cataract and Refractive Surgery (ASCRS) symposium

* Says U.S. FDA has set a target action date under prescription drug user fee act (PDUFA) of July 19, 2017

* There were no treatment-related serious adverse events (SAES) and Dextenza was well tolerated in all clinical trials

* PDUFA date of July 19, 2017 for decision regarding potential approval of Dextenza for treatment of ocular pain following ophthalmic surgery

* Subject to approval of NDA for post-surgical ocular pain by FDA, Ocular Therapeutix intends to submit supplement to NDA for Dextenza

* No patients experienced any adverse events resulting in study withdrawal Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below